VivoSeq
Other

Antiplatelet

0

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Antiplatelet is an early-stage landscape with 0 programs across 4 companies. The most active players are AstraZeneca, Sanofi, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

45

clinical trials

Completed33 · 73%
Unknown status7 · 16%
Recruiting4 · 9%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

45 trials

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
Recruiting·—·Phase 4·NCT06543082·490 enrolled
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
Recruiting·NNavamindradhiraj University·Phase 3·NCT06165068·174 enrolled
Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent
Recruiting·—·N/A·NCT05004233·50 enrolled
The Switching Antiplatelet-9 (SWAP-9) Study
Recruiting·UUniversity of Florida·Phase 4·NCT06588595·90 enrolled
Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial
Not yet recruiting·YYonsei University·N/A·NCT07432516·4,400 enrolled
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)
Completed·SSeoul National University Hospital·Phase 4·NCT02044250·5,530 enrolled
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry
Completed·FFaculty Hospital Kralovske Vinohrady·N/A·NCT02264912·2,016 enrolled
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel
Completed·CCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal·Phase 4·NCT00433784·120 enrolled
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
Completed·—·N/A·NCT05086081·28,389 enrolled
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT01864005·60 enrolled
Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Completed·EECRI bv·Phase 3·NCT02833948·231 enrolled
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00528411·123 enrolled
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
Completed·Sanofi logoSanofi·Phase 3·NCT00335452·25,086 enrolled
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
Completed·JJohns Hopkins University·Phase 4·NCT01894555·33 enrolled
Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin
Completed·RRuttonjee Hospital·Phase 4·NCT01062516·100 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)